Alberto Ascherio, MD, DrPH

Looking to the future of multiple sclerosis care, the panel of thought leaders pose important questions that remain to be answered in the research and treatment of multiple sclerosis.

Expert panelists review the viability of new treatments in development for multiple sclerosis.

Alberto Ascherio, MD, DrPH, addresses the range of latency periods for Epstein-Barr virus and the impact on onset multiple sclerosis.

Alberto Ascherio, MD, DrPH; Anne Cross, MD; and Michael Racke, MD, discuss implications for patient communication and other advances from bench to bedside.

The expert panelists comment on intervention efforts underway to address multiple sclerosis prevention and treatment.

A panel of experts probe the variations in immune response to Epstein-Barr virus in patients with multiple sclerosis.

Alberto Ascherio, MD, DrPH, highlights key risk factors leading to increased prevalence of multiple sclerosis.

Anne Cross, MD, and Michael Racke, MD, discuss how the immune system is primed in multiple sclerosis.

Avindra Nath, MD, explains the importance of understanding virology when treating autoimmune diseases.

Alberto Ascherio, MD, DrPH, recaps key findings and learning from a recently published study that he coauthored demonstrating a causal relationship between MS and Epstein-Barr virus.

Alberto Ascherio, MD, DrPH, and Lawrence Steinman, MD, join NeurologyLive in a conversation about the clinical and research implications of a causative relationship between Epstein-Barr virus and multiple sclerosis.

The professor of epidemiology and nutrition at Harvard TH Chan School of Public Health discussed what might be an optimal dose of vitamin D supplementation in MS, and how vitamin D deficiency should be addressed as a modifiable risk factor.